Clinical Trials Browser

Phase 2 × avapritinib × Other hematologic neoplasm × Clear all

NCT03580655 2025-04-30

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Phase 2 Completed

107 enrolled 1 FDA

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT06783790 2025-01-20

Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06765915 2025-01-09

Avapritinib Maintenance for AML With KIT Mutations

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06221683 2024-08-22

GMCAII

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06316960 2024-08-22

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Phase 2 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05821738 2023-05-09

Avapritinib in CBF-AML With KIT Mutations

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Core Binding Factor Acute Myeloid Leukemia